Pediatric patients receiving a combination of rituximab and cyclophosphamide therapy for rheumatic disease showed clinical improvement with a low risk for adverse effects. While current clinical ...
Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group PURPOSE: Rituximab was recently approved for use in relapsed, low-grade ...
In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results